Insight Molecular Diagnostics
IMDX
22 hedge funds and large institutions have $11.5M invested in Insight Molecular Diagnostics in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.05% less ownership
Funds ownership: 1.07% → 1.02% (-0.05%)
15% less funds holding
Funds holding: 26 → 22 (-4)
47% less capital invested
Capital invested by funds: $21.8M → $11.5M (-$10.3M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$9.06K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.24K |
| 4 |
Morgan Stanley
New York
|
+$396 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$375K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$189K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$125K |
| 4 |
ECM
Element Capital Management
New York
|
-$114K |
| 5 |
Millennium Management
New York
|
-$79K |
IMDX Hedge Fund Activity: Q4 2018 in Review
22 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2018, worth a combined $11.5M — down 47% from $21.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IMDX and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Commonwealth Equity Services, adding an estimated $9.06K. The largest seller was Artal Group, exiting entirely with an estimated $375K sold.
- 22 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2018, down from 26 in Q3 2018.
- Funds reported $11.5M of Insight Molecular Diagnostics stock for Q4 2018, down 47% quarter-over-quarter.
- 2 funds opened new Insight Molecular Diagnostics positions in Q4 2018 and 6 closed out, a net change of -4 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2018 was Commonwealth Equity Services, an estimated $9.06K added.
- The largest Insight Molecular Diagnostics seller in Q4 2018 was Artal Group, an estimated $375K sold.
Based on aggregated 13F filings for Q4 2018.